RedHill Biopharma (RDHL) Accounts Payables (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Accounts Payables for 3 consecutive years, with $1.2 million as the latest value for Q4 2024.

  • Quarterly Accounts Payables fell 64.37% to $1.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2024, down 64.37% year-over-year, with the annual reading at $1.2 million for FY2024, 64.37% down from the prior year.
  • Accounts Payables for Q4 2024 was $1.2 million at RedHill Biopharma, down from $3.3 million in the prior quarter.
  • The five-year high for Accounts Payables was $4.2 million in Q4 2022, with the low at $1.2 million in Q4 2024.
  • Average Accounts Payables over 3 years is $2.9 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Accounts Payables dropped 22.51% in 2023, then plummeted 64.37% in 2024.
  • Over 3 years, Accounts Payables stood at $4.2 million in 2022, then decreased by 22.51% to $3.3 million in 2023, then tumbled by 64.37% to $1.2 million in 2024.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $1.2 million, $3.3 million, and $4.2 million for Q4 2024, Q4 2023, and Q4 2022 respectively.